United States - English - NLM (National Library of Medicine)

avera mckennan hospital - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 5 mg

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - bromocriptine mesilate - tablet - bromocriptine mesilate 2.5 mg - anti-parkinson drugs

United States - English - NLM (National Library of Medicine)

validus pharmaceuticals llc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - parlodel (bromocriptine mesylate) is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. parlodel treatment is indicated in patients with prolactin -secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of parlodel therapy may be used to reduce the tumor mass prior to surgery. parlodel therapy is indicated in the treatment of acromegaly. parlodel therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with parlodel offers potential benefit before the effects of irradiation are manifested. parlodel snaptabs or capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinson’s disease. as adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), parlodel therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing “end of dose failure’’ on levodopa therapy. parlodel therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (“on-off” phenomenon). continued efficacy of parlodel therapy during treatment of more than 2 years has not been established. data are insufficient to evaluate potential benefit from treating newly diagnosed parkinson’s disease with parlodel. studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in parlodel-treated patients than in levodopa/carbidopa-treated patients. patients unresponsive to levodopa are poor candidates for parlodel therapy. hypersensitivity to bromocriptine or to any of the excipients of parlodel (bromocriptine mesylate), uncontrolled hypertension and sensitivity to any ergot alkaloids. in patients being treated for hyperprolactinemia, parlodel should be withdrawn when pregnancy is diagnosed ( s ee precautions, hyperprolactinemic states ) . in the event that parlodel is reinstituted to control a rapidly expanding macroadenoma ( s ee precautions, hyperprolactinemic states ) and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing parlodel must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. when parlodel is being used to treat acromegaly, prolactinoma, or parkinson’s disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. if it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of parlodel is considered to be medically contraindicated. the drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. if the drug is used in the postpartum period, the patient should be observed with caution.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid pregelatinised maize starch

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 11.48mg - capsule - 10 mg - active: bromocriptine mesilate 11.48mg excipient: gelatin magnesium stearate

Canada - English - Health Canada

cobalt pharmaceuticals company - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

Canada - English - Health Canada

cobalt pharmaceuticals company - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

United States - English - NLM (National Library of Medicine)

santarus, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 0.8 mg - cycloset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use - cycloset should not be used to treat type 1 diabetes or diabetic ketoacidosis. - limited efficacy data in combination with thiazolidinediones. - efficacy has not been confirmed in combination with insulin. cycloset is contraindicated in: - patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in cycloset. - patients with syncopal migraine. bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. cycloset is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients. - postpartum patients. serious and life-threatening adverse reactions have been reported with bromocriptine use in this population [see warnings and precautions (5.7), adverse reactions

Singapore - English - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - bromocriptine mesylate eqv bromocriptine - tablet, film coated - 2.5 mg - bromocriptine mesylate eqv bromocriptine 2.5 mg